Login to Your Account

$105M In Milestone Payment

Merck Paying $31M Up Front In Dynavax HBV Vaccine Deal

By Randall Osborne

Friday, November 2, 2007
Dynavax Technologies Corp.'s licensing deal with Merck & Co. Inc. to develop the Phase III hepatitis B virus vaccine Heplisav provides $31.5 million up front with $105 million in potential milestone payments plus royalties, as Dynavax continues managing the pivotal studies and the two firms gear up for a biologics license application filing, possibly in the first quarter of 2009. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription